Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for black caribbean women with aggressive breast cancer: could a different chemo drug work better?

NCT ID NCT07528768

Disease control Sponsor: AntiCancer Research Jamaica Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two chemotherapy drugs—gemcitabine and paclitaxel—in Black Caribbean women with metastatic triple-negative breast cancer. The goal is to see if gemcitabine, usually used later, works better as a first treatment. 750 women from Jamaica, Trinidad, and Barbados will take part, with regular check-ups and scans to track results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 750 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Self-identified Caribbean Black women of Jamaican, Trinidadian, or Barbadian ancestry 2. Age ≥18 years 3. Histologically confirmed metastatic triple-negative breast cancer (recent biopsy required) 4. ECOG (Eastern Cooperative Oncology Group) performance status 0-1 5. No prior systemic therapy for metastatic disease 6. Adequate organ function (detailed laboratory criteria specified) 7. Written informed consent 8. Willingness to provide biospecimens for research Exclusion Criteria: 1. Prior gemcitabine, anthracycline, or taxane treatment in any setting 2. Active brain metastases requiring immediate treatment 3. Pregnant or breastfeeding 4. Concurrent participation in other interventional trials 5. Medical conditions precluding safe chemotherapy administration 6. Inability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic triple-negative breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic triple-negative breast cancer Triple negative breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • St. James Medical Complex

    Port of Spain, Saint James, Trinidad and Tobago

  • The Queen Elizabeth Hospital

    Bridgetown, Saint Michael, Barbados

  • The University of the West Indies, Mona

    Mona, Kingston, Jamaica

More trials for these conditions

Other studies related to the condition(s) this trial covers.